A First-in-Human Study of ZE66-0205 in Healthy Volunteers

Inclusion Criteria: * Written informed consent provided before any study-related activities; able to understand the nature, purpose, risks, and possible adverse effects of the study. * Male or female, 18 to 55 years of age, inclusive, at Screening. * Body mass index 18.0 to 32.0 kg/m², inclusive, and body weight no more than 100 kg at Screening. * Medically healthy in the opinion of the Investigator or delegate based on medical history and absence of clinically significant abnormalities, including: no clinically relevant physical-examination findings; systolic blood pressure 90 to 160 mmHg and diastolic blood pressure 50 to 95 mmHg after at least 5 minutes of rest; pulse rate 40 to 100 beats/minute after at least 5 minutes of rest; tympanic body temperature 35.5°C to 37.7°C; and electrocardiogram without clinically significant abnormalities, including QTcF less than 450 msec for males and less than 470 msec for females. * Female participants must be of non-childbearing potential (surgically sterilised at least 6 weeks before Screening or postmenopausal with confirmatory follicle-stimulating hormone level) or, if of childbearing potential, must have negative pregnancy tests at Screening and Day -1, agree not to become pregnant or donate ova until at least 30 days after the last dose, and use protocol-defined adequate contraception during this period unless exclusively in a same-sex relationship or abstinent as a committed lifestyle. * Male participants must agree not to donat…